pharmaphorum

JANUARY 6, 2022

Roivant is the latest pharma group to take a position in the emerging field of therapies targeted at RNA splicing, licensing exclusive rights to a drug developed by a unit of Japanese drugmaker Eisai. . The post Roivant joins RNA splicing push with Eisai deal appeared first on.

RNA 52

RNA Licensing Licensing Development 52

Roots Analysis

OCTOBER 30, 2023

In the past few years, Next Generation RNA therapeutics have emerged as one of the key therapeutic modalities in the modern healthcare industry. These RNA based therapeutics play a crucial role in protein production and regulation of gene functions.

RNA 40

RNA Vaccination Vaccine Development 40

pharmaphorum

DECEMBER 1, 2020

The filing for a conditional marketing authorisation completed the rolling submission process that began on October 6. The EMA has also confirmed it has received a filing from Moderna, which is producing a rival vaccine based on similar RNA technology.

Vaccination 88

Vaccination Vaccine RNA Clinical Trials 88

XTalks

JANUARY 3, 2024

In individuals affected by ATTR, which includes both hereditary and wild-type (non-hereditary) variants, the TTR protein forms fibrils that accumulate in various tissues. These tissues comprise peripheral nerves, the heart, gastrointestinal system, eyes, kidneys, central nervous system, thyroid and bone marrow.

FDA Approval 105

FDA Approval Protein RNA Clinical Trials 105

pharmaphorum

JANUARY 7, 2022

billion licensing agreement with Ionis that gave it rights to eplontersen , a follow-up to Ionis’ already-marketed Tegsedi (inotersen) for polyneuropathy, another common complication of ATTR. Tafamidis is thought to work by stabilising the misfolded proteins. The new agreement comes just days after AZ closed a $3.1

Antibody 116

Antibody Licensing Licensing Protein 116

pharmaphorum

MARCH 9, 2022

BIVV001 is a factor VIII replacement therapy that is being developed as a successor to Eloctate (efmoroctocog alfa), Sanofi and Sobi’s current factor VIII drug that is dosed every four days but has seen its sales decline in an increasingly competitive market. The half life of the new drug – one of the main draws for Sanofi’s $11.6

Protein 98

Protein Gene Therapy Sales Regulation 98

pharmaphorum

OCTOBER 31, 2022

VRG50635 was discovered using Verge’s AI-powered discovery platform ConVERGE which maps out the biological underpinnings of diseases using data on DNA, RNA and protein profiles to identify new targets and drug that can interact with them. Alice Zhang.

Genome 136

Genome Genomics Drugs RNA 136

XTalks

NOVEMBER 22, 2021

Related: How RNA-Based Pesticides Can Improve Pest Control. Once the army of Black Soldier flies has finished feasting, Bardee transforms the leftovers into “all-natural protein and oil for pet food, poultry and aqua feed and nutrient-rich organic fertilizers,” according to the company’s website.

Protein 98

Protein RNA Engineer Production 98

Delveinsight

FEBRUARY 8, 2021

Analysts at DelveInsight expect major changes in the Cystic Fibrosis market landscape in the foreseeable future. The major factors shaping the market outlook include prevalence, monopoly of a pharma company, diagnostics and screening methodologies, entry of other market players in the Cystic Fibrosis market domain, as well as restraints.

Marketing 52

Marketing Development Production Drugs 52

Roots Analysis

MARCH 16, 2023

It is important in the process of protein synthesis because mRNA is responsible for transferring genetic information from DNA to ribosomes, which then decodes the genetic information into a protein. Messenger ribonucleic acid (mRNA) is a single-stranded molecule that is complementary to a gene’s DNA.

Vaccination 52

Vaccination Vaccine DNA Protein 52

Delveinsight

JANUARY 18, 2021

The present Angelman syndrome treatment market revolves around the management of symptoms rather than curing the condition. . Several pharmaceutical and biotech companies in the Angelman syndrome market are exploring the novel curative approaches.

Marketing 52

Marketing Gene Drugs Protein 52

pharmaphorum

JANUARY 6, 2021

million – including $175 million upfront and an equity investment of $50 million – to find multiple RNA interference (RNAi) candidates for diseases like non-alcoholic steatohepatitis (NASH) and type 2 diabetes. Danish drugmaker Novo Nordisk signed a deal with the US biotech in 2019 valued at up to $675.5

Gene Silencing 66

Gene Silencing Gene RNA Contract Manufacturing 66

Delveinsight

JULY 29, 2021

The acquisition of Teneobio will bolster their ability to develop innovative medicines to treat patients with serious illnesses and to bring to market best-in-class products, particularly concerning multispecific and bispecific medicines directed against targets in a broad range of diseases across their core therapeutic areas, as said by David M.

Drugs 98

Drugs Protein Life Science Development 98

pharmaphorum

MARCH 1, 2021

COVID-19 antigen tests diagnose active infection by detecting SARS-CoV-2 viral proteins in samples, as opposed to PCR tests which detect viral RNA and require lab processing, but can miss infections with low virus levels.

In-Vitro 98

In-Vitro RNA Protein Antibody 98

pharmaphorum

NOVEMBER 17, 2020

Both Pfizer and Moderna vaccines use synthetic messenger RNA to activate the immune system against the virus. They both code for the “Spike” protein seen on the surface of the SARS-CoV-2 coronavirus, which causes the body to produce antibodies that neutralise the virus in the event of an infection.

Vaccination 77

Vaccination Vaccine RNA Clinical Trials 77

The Pharma Data

OCTOBER 14, 2020

is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA.

Protein 52

Protein RNA Production Genetics 52

pharmaphorum

SEPTEMBER 21, 2020

The drug works by reducing the production of ApoC-III, a protein that regulates plasma triglycerides. Akcea – an affiliate of Ionis that is set to become a wholly-owned subsidiary shortly – specialises in antisense drugs that target RNA to prevent the expression of errant genes that cause diseases.

Drugs 80

Drugs RNA Medicine Genetics 80

Roots Analysis

AUGUST 28, 2022

Furthermore, several live cell imaging and non-destructive fluorescence histological methods measure limited number of biomarkers at a time and the tags introduced may interfere with the natural function of genes and proteins. Likely Growth of the Spatial Omics Solutions Market. Our Social Media Platform.

Genome 52

Genome Genomics RNA Genome Project 52

Delveinsight

JANUARY 7, 2021

The startup recently raised USD 87 million to propel itself in a competitive market. It also slates to commence a Phase Ib trial of its second candidate, TERN-201, a vascular adhesion protein (VAP-1) inhibitor, with top-line data anticipated in the first half of 2022. Terns raises USD 87 Million for NASH drugs.

RNA 52

RNA Clinical Trials Clinical Trials Bioavailability 52

pharmaphorum

FEBRUARY 19, 2021

billion cumulative doses of its NVX-CoV2373 recombinant protein-based vaccine candidate, which is yet to be approved by regulators. It can be stored at standard refrigerator temperatures and does not require the ultra-cool supply chain required to maintain stability of RNA vaccines from Pfizer/BioNTech and Moderna.

Vaccination 80

Vaccination Vaccine Manufacturing RNA 80

pharmaphorum

DECEMBER 7, 2020

All the vaccines developed in China are inactivated, meaning they are made of proteins found on the surface of the coronavirus that produce a response that provides immunity in the event of an infection. This means they do not require the ultra-cool temperatures needed to store the RNA-based vaccines from Pfizer/BioNTech and Moderna.

Vaccination 59

Vaccination Vaccine Production Clinical Development 59

Roots Analysis

FEBRUARY 18, 2022

In the 20 th century, major research went into discovery of a therapeutic class with the primary purpose of interfering with the RNA expression linked to disease causing proteins, nowadays classified as oligonucleotides. Oligonucleotide Synthesis, Modification and Purification Services Market. Our Social Media Platform.

Contract Manufacturing 52

Contract Manufacturing Manufacturing Drug Delivery Systems RNA 52

Roots Analysis

MARCH 8, 2023

INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA , based on the type of cell of their origin and its conditions. Exosomes convey a wide range of information to the target cells, depending on their source.

RNA 52

RNA Drug Delivery DNA Development 52

The Pharma Data

DECEMBER 8, 2020

The fully integrated pharmaceutical company creates value through China’s specialty pharmaceutical markets with focus on iron deficiency, pain management and respiratory. Cornering the untapped Chinese CNS market, SciNeuro launched with $100 million in their pocket. SciNeuro Pharmaceuticals . Pear Therapeutics.

RNA 52

RNA Antibody Life Science Protein 52

Roots Analysis

AUGUST 12, 2024

Molecular diagnostic tests refer to tests intended to detect specific sequences in human genomic samples, such as DNA or RNA, in order to diagnose a particular disease. It is worth mentioning that molecular diagnostics is a subset of the broader in vitro diagnostics market.

Genetics 40

Genetics Gene Expression RNA DNA 40

The Pharma Data

JULY 6, 2021

New research from first-in-class marketed and investigational therapies in hemophilia, immune thrombocytopenia and acquired thrombotic thrombocytopenic purpura will be presented. Sanofi’s two marketed extended half-life factor replacement therapies shifted a two-decades-old treatment paradigm when launched in 2014.

Protein 52

Protein RNA Development Marketing 52

pharmaphorum

OCTOBER 12, 2021

It was the first drug to be approved in the US that works by RNA interference – blocking the strand of RNA that transcribes a defective gene in a patient’s DNA into a misfolded protein that leads to a disease.

RNA 52

RNA DNA Drugs Protein 52

The Pharma Data

JANUARY 22, 2021

As research developments into RNA vaccines help scientists accelerate drug candidates to arm the immune system against coronavirus, Pharma IQ ’s Keeping tabs on Covid-19 update returns with news from some of the biotechnology innovators leading the fight against the global pandemic. Download this exclusive report here.

Vaccination 52

Vaccination Vaccine Protein Immune Response 52

Pharmaceutical Technology

MARCH 8, 2023

Caris’s platform combines data obtained from protein analysis, whole exome sequencing, artificial intelligence (AI) models and signatures, and whole transcriptome sequencing for improving patient outcomes through personalised medicine advancement. Please check your email to download the Whitepaper.

Research 130

Research Clinical Trials Clinical Trials Life Science 130

pharmaphorum

MARCH 11, 2022

Due to its above 90% efficacy at preventing shingles, the vaccine quickly became a blockbuster success for the company, to such a degree that Pfizer and BioNTech are now looking to establish themselves in the same market. Now, the pipeline for products in infectious diseases is growing once again.

Vaccination 81

Vaccination Vaccine Development Manufacturing 81

pharmaphorum

JULY 11, 2022

Sanofi R&D in its core haemophilia category is advancing on three fronts – engineered proteins, RNA interference drugs and gene therapies – and highlighted results in two of those at the International Society on Thrombosis and Haemostasis (ISTH) congress over the weekend.

Engineer 52

Engineer Gene Therapy Sales Drugs 52

pharmaphorum

JANUARY 19, 2023

Amvuttra (vutrisiran) is a follow-up to Alnylam’s earlier RNA interference (RNAi) ATTR amyloidosis therapy Onpattro (patisiran), which was cleared by NICE for NHS use in 2019, but offers a simpler, more patient-friendly dosing regimen.

Gene Silencing 52

Gene Silencing RNA Protein Production 52

The Pharma Data

SEPTEMBER 30, 2021

The function of the adjuvant is to market the body’s immune reaction. “We used NanoSTING because the adjuvant for intranasal vaccination and single-cell RNA-sequencing to verify the nasal-associated lymphatic tissue as an inductive site upon vaccination. Varadarajan is co-founder of AuraVax Therapeutics Inc.,

Vaccination 52

Vaccination Vaccine Immune Response Licensing 52

The Pharma Data

OCTOBER 19, 2020

The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions. Europe , Asia and other international markets.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

pharmaphorum

NOVEMBER 23, 2021

The bolt-on deal comes – which includes an upfront payment of $120 million and up to $910 million in milestones – covers rights to ARO-HSD, Arrowhead’s RNA interference drug targeting an enzyme called HSD17B13 that seems to contribute to the pathology of NASH and other liver diseases.

Sales 52

Sales Drugs Trials RNA 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

The Pharma Data

JANUARY 6, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the European Commission has granted a conditional marketing authorization (CMA) for COVID-19 Vaccine Moderna, allowing vaccination programs using the Moderna vaccine to be rolled out across the European Union.

Vaccination 52

Vaccination Vaccine Medicine Containment 52